DexCom, Inc. (NASDAQ:DXCM) Q1 2024 Earnings Call Transcript

Page 4 of 4

Certainly if we go to the tender system in Europe, there is a two-tiered system in many countries. We offered the Dexcom ONE product there at lower price point to be able to address those in AID systems, and our AID pricing in those countries, we have prices set for G7, that are said in the tender process. So, we are very comfortable where we are in those as well.

Operator: And there are no further questions at this time. I’ll now turn the call back to Mr. Kevin Sayer for closing remarks.

Kevin Sayer: Thanks everybody for participating in our call today. This really was a great quarter for DexCom as we continue to drive the most important innovations in our industry. We are continuing to widen the gap between DexCom and our competitors by driving more first in our CGM user experience, particularly in the G7 platform. Direct to Watch has been the most requested addition through our experience, ever since we lunched G5 many years ago, and now it’s here. Our users are going to be able to, as I just articulated, have an incredibly discrete experience with CGM on Apple Watch only, and that will include all of our Share follow system as well. So, imagine again, a parent who wants to send their kid to school without a phone, they’ll be able to do everything on a watch that they used to be able to do on their phone.

Access to CGM on a global basis continues to expand. We are very well-positioned with our product portfolio to win these opportunities. And lastly, I just want to talk a bit about Stelo. We went from a December filing with the FDA on Stelo to a March approval for the first over-the-counter CGM product platform in the United States. This is going to greatly enhance the lives of many, many people, and we will learn so much about it during this launch in 2024. We will be very well-positioned in ’25 and years going forward. And let’s not forget at this call, we continue to deliver outstanding worldwide top-line growth, continued growth operating margin expansion, at the same time, we have not at all skimmed on investing on our future products and R&D, and we have a very strong commitment to creating the scale necessary to drive this business where it needs to get and pursue all of our opportunities.

Thanks, everybody, and we appreciate your support on the call today.

Operator: And ladies and gentlemen, this concludes today’s call, and we thank you for your participation. You may now disconnect.

Follow Dexcom Inc (NASDAQ:DXCM)

Page 4 of 4